Award
National Cancer Institute 1R44CA310319-01
The SynthNode Paradigm: Reimagining CAR T Cell Therapy for Improved Patient Outcomes
Recipient
Persistence Therapeutics, Inc.
Award Amount
$314,685.00
Ceiling
$314,685.00
Awarded
September 22, 2025
Identifier
1R44CA310319-01
Grant awarded to Persistence Therapeutics, Inc. for developing an implantable device to enhance CAR T cell therapy, funded by NCI with $314,685 for the period 2025-09-22 to 2026-08-31.
Description
This is a grant award for a project titled "The SynthNode Paradigm: Reimagining CAR T Cell Therapy for Improved Patient Outcomes" funded by the National Cancer Institute (NCI). The project aims to develop an implantable device to improve CAR T cell therapy for cancer treatment. The project duration is from September 22, 2025, to August 31, 2026. The total funding amount is approximately $314,685. The project involves collaboration with regulatory and manufacturing experts to bring the device from proof-of-concept to clinical trials.